Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (31-40 of 188) with videos related to

Pageof 19
Sort By:
Clinical Chemistry and Laboratory Medicine|September 2, 2020
Determination of free light chains: assay-dependent differences in interpretationXavier Bossuyt, Koen Poesen, Ben Sprangers, et al.
Case Reports in Hematology|June 14, 2016
Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple MyelomaJan Van Keer, Michel Delforge, Daan Dierickx, et al.
Acta Clinica Belgica|February 10, 2025
Suspect the unexpected: proliferative glomerulonephritis with monoclonal immunoglobulin deposits and a negative hematological work-up. A case of monoclonal gammopathy of renal significanceBenoît Delforge, Elien Mahieu, Amélie Dendooven, et al.
European Heart Journal. Case Reports|March 18, 2022
Case report: Two sisters with light-chain cardiac amyloidosis, a mere coincidence?Sarah Cappuyns, Matthias Verbesselt, Alexander Van De Bruaene, et al.
Leukemia|August 31, 2019
Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturationNicolas G Kint, Elien Heylen, Daniele Pepe, et al.
Annals of Hematology|August 6, 2017
Blinatumomab in relapsed/refractory diffuse large B cell lymphomaRuben Van Dijck, Ann Janssens, Daan Dierickx, et al.
Oncotargets and Therapy|March 21, 2022
Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma PatientsMichel Delforge, Jolien Raddoux, Corine Antonis, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|September 26, 2009
Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disordersPieter Vermeersch, Martine Vercammen, Annelies Holvoet, et al.
Leukemia|April 21, 2018
Diagnostic thresholds for free light chains in multiple myeloma depend on the assay usedXavier Bossuyt, Michel Delforge, Martin Reynders, et al.
Clinical Chemistry and Laboratory Medicine|April 22, 2018
Antigen excess detection by automated assays for free light chainsXavier Bossuyt, Michel Delforge, Martin Reynders, et al.
Pageof 19

Showing results (31-40 of 188) with videos related to

Sort By:
Pageof 19
Clinical Chemistry and Laboratory Medicine|September 2, 2020
Determination of free light chains: assay-dependent differences in interpretationXavier Bossuyt, Koen Poesen, Ben Sprangers, et al.
Case Reports in Hematology|June 14, 2016
Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple MyelomaJan Van Keer, Michel Delforge, Daan Dierickx, et al.
Acta Clinica Belgica|February 10, 2025
Suspect the unexpected: proliferative glomerulonephritis with monoclonal immunoglobulin deposits and a negative hematological work-up. A case of monoclonal gammopathy of renal significanceBenoît Delforge, Elien Mahieu, Amélie Dendooven, et al.
European Heart Journal. Case Reports|March 18, 2022
Case report: Two sisters with light-chain cardiac amyloidosis, a mere coincidence?Sarah Cappuyns, Matthias Verbesselt, Alexander Van De Bruaene, et al.
Leukemia|August 31, 2019
Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturationNicolas G Kint, Elien Heylen, Daniele Pepe, et al.
Annals of Hematology|August 6, 2017
Blinatumomab in relapsed/refractory diffuse large B cell lymphomaRuben Van Dijck, Ann Janssens, Daan Dierickx, et al.
Oncotargets and Therapy|March 21, 2022
Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma PatientsMichel Delforge, Jolien Raddoux, Corine Antonis, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|September 26, 2009
Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disordersPieter Vermeersch, Martine Vercammen, Annelies Holvoet, et al.
Leukemia|April 21, 2018
Diagnostic thresholds for free light chains in multiple myeloma depend on the assay usedXavier Bossuyt, Michel Delforge, Martin Reynders, et al.
Clinical Chemistry and Laboratory Medicine|April 22, 2018
Antigen excess detection by automated assays for free light chainsXavier Bossuyt, Michel Delforge, Martin Reynders, et al.
Pageof 19